Last reviewed · How we verify
Conventional fecal microbiota transplantation — Competitive Intelligence Brief
phase 3
Microbiota-based therapeutic
Gastroenterology / Infectious Disease
Biologic
Live · refreshed every 30 min
Target snapshot
Conventional fecal microbiota transplantation (Conventional fecal microbiota transplantation) — University of Pecs. Fecal microbiota transplantation restores a healthy gut microbiome by introducing diverse bacterial communities from a donor to treat dysbiosis-related conditions.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Conventional fecal microbiota transplantation TARGET | Conventional fecal microbiota transplantation | University of Pecs | phase 3 | Microbiota-based therapeutic |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Microbiota-based therapeutic class)
- University of Pecs · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Conventional fecal microbiota transplantation CI watch — RSS
- Conventional fecal microbiota transplantation CI watch — Atom
- Conventional fecal microbiota transplantation CI watch — JSON
- Conventional fecal microbiota transplantation alone — RSS
- Whole Microbiota-based therapeutic class — RSS
Cite this brief
Drug Landscape (2026). Conventional fecal microbiota transplantation — Competitive Intelligence Brief. https://druglandscape.com/ci/conventional-fecal-microbiota-transplantation. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab